CA2692814A1 - Purification du facteur viii a l'aide d'une resine en mode mixte ou multimodal - Google Patents

Purification du facteur viii a l'aide d'une resine en mode mixte ou multimodal Download PDF

Info

Publication number
CA2692814A1
CA2692814A1 CA 2692814 CA2692814A CA2692814A1 CA 2692814 A1 CA2692814 A1 CA 2692814A1 CA 2692814 CA2692814 CA 2692814 CA 2692814 A CA2692814 A CA 2692814A CA 2692814 A1 CA2692814 A1 CA 2692814A1
Authority
CA
Canada
Prior art keywords
factor viii
protein
salt
purification
ethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692814
Other languages
English (en)
Inventor
Susanne Bang
Lars Thim
Johan Karlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk A/S
Susanne Bang
Lars Thim
Johan Karlsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S, Susanne Bang, Lars Thim, Johan Karlsson filed Critical Novo Nordisk A/S
Publication of CA2692814A1 publication Critical patent/CA2692814A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA 2692814 2007-07-11 2008-07-11 Purification du facteur viii a l'aide d'une resine en mode mixte ou multimodal Abandoned CA2692814A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07112287.3 2007-07-11
EP07112287 2007-07-11
PCT/EP2008/059094 WO2009007451A1 (fr) 2007-07-11 2008-07-11 Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal

Publications (1)

Publication Number Publication Date
CA2692814A1 true CA2692814A1 (fr) 2009-01-15

Family

ID=38472947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692814 Abandoned CA2692814A1 (fr) 2007-07-11 2008-07-11 Purification du facteur viii a l'aide d'une resine en mode mixte ou multimodal

Country Status (15)

Country Link
US (1) US8399620B2 (fr)
EP (1) EP2167526B1 (fr)
JP (1) JP5323072B2 (fr)
KR (1) KR101293504B1 (fr)
CN (1) CN101730707B (fr)
AT (1) ATE503763T1 (fr)
AU (1) AU2008274195B2 (fr)
BR (1) BRPI0814220B8 (fr)
CA (1) CA2692814A1 (fr)
DE (1) DE602008005885D1 (fr)
ES (1) ES2364118T3 (fr)
NL (1) NL300663I2 (fr)
PL (1) PL2167526T3 (fr)
RU (1) RU2493163C2 (fr)
WO (1) WO2009007451A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066417B (zh) 2008-06-24 2015-11-25 奥克塔法马股份有限公司 提纯凝固因子viii的方法
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
KR101856260B1 (ko) 2010-02-24 2018-05-09 치에시 파마슈티시 에스.피.아. 재조합 리소좀 알파-만노시다제의 제조 및 정제 방법
ES2610529T3 (es) 2010-03-30 2017-04-28 Octapharma Ag Un procedimiento de purificación de proteínas dependientes de vitamina K, tales como el factor de coagulación IX
WO2011121031A1 (fr) 2010-03-30 2011-10-06 Octapharma Ag Procédé de purification d'une protéine de facteur de croissance
WO2012059495A1 (fr) * 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Procédé optimisé pour la capture d'anticorps par une chromatographie en mode mixte
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
WO2013075740A1 (fr) 2011-11-23 2013-05-30 Sanofi Procédé de purification d'anticorps
US20150275195A1 (en) 2012-10-24 2015-10-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN103396494B (zh) * 2013-04-27 2015-04-01 江苏省疾病预防控制中心 一种凝血因子ix的单克隆抗体
BR112015027812B1 (pt) * 2013-05-06 2021-03-30 Sanofi Método para a purificação de uma proteína a partir de uma solução
SG11201610431WA (en) * 2014-06-25 2017-01-27 Jhl Biotech Inc Methods and reagents for purification of proteins
PL3177317T3 (pl) 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
EP3205665A1 (fr) * 2016-02-11 2017-08-16 Octapharma AG Procédé de séparation de facteur viii à partir de produits sanguins
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
WO2021001522A1 (fr) 2019-07-04 2021-01-07 CSL Behring Lengnau AG Facteur de von willebrand (vwf) tronqué pour augmenter la stabilité in vitro du facteur viii de coagulation
WO2021094344A1 (fr) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides pour induire une tolérance au facteur viii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302006D0 (sv) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab Protein formulation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE503424C2 (sv) 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
EP1831242B1 (fr) * 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction du contenu en contaminants proteiques de compositions renfermant une proteine d'interet dependante de la vitamine k
EP1707634A1 (fr) * 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
CN102066417B (zh) 2008-06-24 2015-11-25 奥克塔法马股份有限公司 提纯凝固因子viii的方法

Also Published As

Publication number Publication date
KR101293504B1 (ko) 2013-08-07
KR20100051620A (ko) 2010-05-17
NL300663I2 (fr) 2016-09-22
DE602008005885D1 (de) 2011-05-12
EP2167526B1 (fr) 2011-03-30
WO2009007451A1 (fr) 2009-01-15
CN101730707B (zh) 2014-12-17
JP2010533150A (ja) 2010-10-21
BRPI0814220A2 (pt) 2015-01-06
ATE503763T1 (de) 2011-04-15
RU2010103528A (ru) 2011-08-20
BRPI0814220B1 (pt) 2019-09-17
ES2364118T9 (es) 2014-05-19
EP2167526A1 (fr) 2010-03-31
US8399620B2 (en) 2013-03-19
AU2008274195A1 (en) 2009-01-15
ES2364118T3 (es) 2011-08-25
CN101730707A (zh) 2010-06-09
PL2167526T3 (pl) 2011-09-30
RU2493163C2 (ru) 2013-09-20
AU2008274195B2 (en) 2013-09-05
JP5323072B2 (ja) 2013-10-23
US20100204452A1 (en) 2010-08-12
BRPI0814220B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AU2008274195B2 (en) Purification of factor VIII using a mixed-mode or multimodal resin
KR101804136B1 (ko) 응고 인자 ｖｉｉｉ을 정제하는 방법
JP5730211B2 (ja) ウイルスのアルギニン不活化
Burnouf‐Radosevich et al. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate
US11479578B2 (en) Protein purification and virus inactivation with alkyl glycosides
US20130079498A1 (en) Process for purifying vitamin k dependent proteins such as coagulation factor ix
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
JP2008511546A (ja) タンパク質単離のためのプロセス
JP7144113B2 (ja) 血液製剤から第ｖｉｉｉ因子を分離する方法
EA040179B1 (ru) Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro
WO2018069700A1 (fr) Procédé de purification de fviii

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140711